

FDA approves Gavreto for metastatic RET fusion-positive NSCLC

written by CAP TODAY
December 17, 2020

December 2020—Roche announced FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA-approved test. Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.

Approval is based on the results from the phase one/two ARROW study, in which Gavreto produced durable clinical responses in people with RET fusion-positive NSCLC with or without prior therapy and regardless of RET fusion partner or central nervous system involvement.

Gavreto is jointly commercialized by Genentech and Blueprint Medicines.

[*Genentech, 877-436-3683*](#)

[*Blueprint Medicines, 617-374-7580*](#)



©2026 CAP TODAY, all rights reserved.